HPLC法同时测定双金连合剂中11种成分的含量

目的:建立反相高效液相色谱法同时测定双金连合剂中新绿原酸、绿原酸、隐绿原酸、连翘苷、芦丁、异绿原酸B、异绿原酸A、异绿原酸C、黄芩苷、牡荆素和黄芩素的含量。方法:采用Phenomenex ODS C18色谱柱(4.6 mm×250 mm,5μm),以乙腈(A)-0.4%磷酸(B)为流动相,梯度洗脱(0~10 min,5%A→9%A;10~30 min,9%A;30~60 min,9%A→30%A;60~90 min,30%A→50%A),流速1.0 m L·min-1,最大吸收波长下检测(新绿原酸、绿原酸和隐绿原酸:327 nm;异绿原酸B、A、C:330 nm;芦丁、黄芩苷和黄芩素:280 nm;连翘苷:277 nm;牡荆素:350 nm)。结果:11种待测成分质量浓度与峰面积在测定范围内均呈良好线性关系(r≥0.999 0),平均回收率为96.7%~101.6%(RSD≤2.8%)。结论:该方法经方法学验证可为更好地控制双金连合剂的质量提供参考依据。     

HPLC程序波长法同时测定黄连解毒汤中栀子苷和4种黄酮类成分的含量

目的:建立一种同时检测黄连解毒汤中栀子苷、黄芩苷、汉黄芩苷、黄芩素和汉黄芩素含量的 HPLC 方法。方法:采用Kromasil C_(18)色谱柱(150 mm×4.6 mm,5 μm),以乙腈(A)-5 mmol·L~(-1)磷酸二氢钠溶液(含0.05%磷酸,pH 3.0)(B)为流动相,线性梯度洗脱(0～8.5 min,86.5%B;8.5～17.0 min,86.5%B→80%B;17～30 min,80%B;30～40 min,80%B→60%B;40～51 min,60%B→52%B;51～55 min,52%B→42%B;55～60 min,42%B→86.5%B;60～65 min,86.5%B),流速1.0 mL·min~(-1),程序可变波长紫外检测(0～15 min,238 nm;15～50 min,276 nm)。结果:在58 min 内黄连解毒汤中栀子苷、黄芩苷、汉黄芩苷、黄芩素和汉黄芩素5种成分被完全分离;回归方程显示5种成分的峰面积与其浓度呈良好的线性;5种成分的加样叫收率(n=15)分别为102.2%,97.56%,98.61%,97.85%,98.41%;RSD 小于5.0%。结论:利用程序可变波长检测,建立了一种可靠的同时测定黄连解毒汤中5种标志性成分含量的 HPLC 方法。     

HPLC法同时测定气管炎丸中6个活性成分的含量

目的:建立HPLC法同时测定气管炎丸中绿原酸、芍药苷、柚皮苷、黄芩苷、黄芩素、汉黄芩素的含量。方法:采用Agilent 5 TC-C₁₈(2)(250 mm×4.6 mm,5μm)色谱柱,以乙腈(A)-0.2%磷酸水溶液(B)为流动相,梯度洗脱(0~50 min,2%A→34%A;50~61 min,34%A→55%A;61~62 min,55%A→2%A;62~66 min,2%A),流速1.0 mL·min^-1,柱温30℃,检测波长分别为327 nm(绿原酸)、230 nm(芍药苷)和280 nm(柚皮苷、黄芩苷、黄芩素、汉黄芩素),进样体积10μL。结果:6个活性成分在相应浓度范围内线性关系良好(r>0.999);绿原酸、芍药苷、柚皮苷、黄芩苷、黄芩素、汉黄芩素的平均回收率分别为101.0%(RSD=1.3%)、99.2%(RSD=1.1%)、98.3%(RSD=1.4%)、99.9%(RSD=1.3%)、101.2%(RSD=1.3%)、101.5%(RSD=1.3%);精密度、稳定性、重复性良好,RSD均小于2%。含量测定结果分别为0.2959~0.3758、0.7114~0.8184、0.3614~0.4892、1.169~1.555、0.03576~0.05287、0.1021~0.1675 mg·g^-1。结论:该方法简单、准确、快速,可为气管炎丸后续质量标准的提高提供实验参考。     

双波长RP-HPLC法测定清开灵胶囊中栀子苷和黄芩苷的含量

目的建立测定清开灵胶囊黄芩苷和栀子苷含量的RP-HPLC法。方法色谱柱:Hibor C18键合硅胶柱(4.6 mm×160 mm,5μm)。流动相:A相为0.2%磷酸水溶液,B相为乙腈。采用梯度洗脱,流动相:0~10min:B相-A相(12∶88),流速0.8 mL/min;10 min之后:B相-A相(25∶75),流速:1.0 mL/min。检测波长:240 nm(栀子苷)、278 nm(黄芩苷)。柱温:30℃。结果栀子苷在0.16~2.4μg范围内线性关系良好,平均加样回收率为96.94%,RSD=2.08%(n=6),黄芩苷在0.18~2.7μg范围内线性关系良好,平均加样回收率为100.18%,RSD=2.01%(n=6)。结论本法简便、快速、灵敏,精密度和重现性良好,专属性强,准确度高,可作为该制剂有效成分的含量测定控制方法。     

清开灵注射液质量评价研究

目的建立清开灵注射液中测定胆酸、栀子苷、黄芩苷含量的HPLC方法,对不同厂家生产的样品进行质量评价。方法测定胆酸用C_(18) YMC—Pack ODS—A色谱柱,乙腈-水-磷酸(35:65:0.1)为流动相,检测波长192nm;测定栀子苷用C_(18)色谱柱,流动相为乙腈-水(10:90),检测波长238nm;测定黄芩苷用SUPELCO C_(18)色谱柱,甲醇-水-磷酸(47:53:0.2)为流动相,检测波长276nm。结果胆酸平均回收率为97.63％,RSD为1.73％;栀子苷平均回收率为98.15％,RSD为1.64％;黄芩苷平均回收率为99.06％,RSD为1.27％。结论本方法灵敏、准确、简便,可用于清开灵注射液质量控制。     

HPLC同时测定龙胆泻肝丸(浓缩丸)中龙胆苦苷、栀子苷和黄芩苷的含量

目的:建立同时测定龙胆泻肝丸(浓缩丸)中龙胆苦苷、栀子苷和黄芩苷的高效液相色谱分析方法.方法:采用安捷伦C 18(4.6mm×250mm,5μm)色谱柱,以甲醇(A)-0.2％磷酸溶液(B)为流动相,梯度洗脱(0～25min,20％A;25～30min,20％A→43％A;30～50min,43％A),流速:1.0mL/min,检测波长分别为280nm(黄芩苷、龙胆苦苷)和238nm(栀子苷);柱温:30℃.结果:龙胆苦苷在0.31754～3.1754μg之间线性关系良好,r=0.9996,栀子苷在0.16760～1.6760μg之间线性关系良好,r=0.9995,黄芩苷在0.16836～1.6836μg之间线性关系良好,r=0.9996,龙胆苦苷的平均回收率为98.63％,RSD=0.83％,栀子苷的平均回收率为97.98％,RSD=0.94％,黄芩苷的平均回收率为97.90％,RSD=1.02％.结论:该方法操作简单,重复性好,准确度高,分离效果好,可以用于龙胆泻肝丸(浓缩丸)的质量控制.     

HPLC法同时测定舒肝宁注射液中5种成分的含量

目的:建立同时测定舒肝宁注射液中5种成分含量的方法。方法:采用高效液相色谱法。色谱柱为Symmetry~? C_(18),流动相为甲醇-0.4%磷酸溶液(梯度洗脱),流速为1.0 mL/min,检测波长为238 nm(栀子苷、黄芩苷)、327 nm(绿原酸、野黄芩苷、黄芩素),柱温为30℃,进样量为10μL。结果:绿原酸、栀子苷、黄芩苷、黄芩素、野黄芩苷检测质量浓度线性范围分别为0.406 2~26.0μg/mL(r=0.999 9)、2.500 0~160.0μg/mL(r=0.999 9)、6.562 0~420.0μg/mL(r=0.999 9)、0.312 5~20.0μg/mL(r=0.9996)、0.585 9~37.5μg/mL(r=0.999 8);定量限≤31.20 ng,检测限≤15.60 ng;精密度、稳定性、重复性试验的RSD<2.0%;加样回收率分别为97.72%~101.10%(RSD=1.21%,n=6)、97.67%~102.40%(RSD=1.87%,n=6)、97.64%~101.10%(RSD=1.31%,n=6)、96.45%~100.10%(RSD=1.47%,n=6)、96.16%~101.10%(RSD=1.69%,n=6)。结论:该方法操作简便,精密度、稳定性、重复性好,可用于舒肝宁注射液中5种成分含量的同时测定。     

高效液相色谱法测定舒肝宁注射液中黄芩苷和栀子苷含量

目的:建立高效液相色谱法测定舒肝宁注射液中黄芩苷和栀子苷含量。方法:A tlan tisTMdC18柱,4.6×150mm,5μ;黄芩苷流动相为0.01m o l/L磷酸盐缓冲液(pH 2.8)-甲醇(60:40),流速1m l/m in,检测波长280nm;栀子苷流动相为甲醇-水-冰醋酸(20:80:0.5),流速1m l/m in,检测波长238nm。结果:黄芩苷和栀子苷线性范围分别为30~100μg/m l、30~150μg/m l,平均回收率分别为99.68%、99.66%。结论:该法简便快速、结果准确,适合舒肝宁注射液的质量控制。     

高效液相色谱程序可变波长法测定银黄颗粒中绿原酸和黄芩苷的含量

目的:测定银黄颗粒中绿原酸、黄芩苷的含量。方法:利用二极管阵列检测器的程序可变波长功能,在绿原酸、黄芩苷的最大吸收波长(λmax)同时测定银黄颗粒中绿原酸、黄芩苷含量。HiQsilC18色谱柱;柱温为30℃;流动相为甲醇(A)-0.2%磷酸(B);流速为1mL.min-1;梯度洗脱,0～5min,40%A;5～15min,40%A线性增加至80%A;15min后,80%A;检测波长程序设置为0～5min,327nm(绿原酸);5～15min,280nm(黄芩苷)。结果:绿原酸进样量在0.072～0.72μg范围内线性关系良好(r=0.9999),黄芩苷进样量在0.91～9.1μg范围内线性关系良好(r=0.9999),绿原酸、黄芩苷平均加样回收率为98.0%,97.6%,RSD分别为1.43%,1.87%。结论:该方法简便、准确,具有较好的重复性,可作为银黄颗粒制剂的质量控制方法。     

双波长反相高效液相色谱法同时测定蓝芩口服液中栀子苷、绿原酸和黄芩苷含量

目的：建立双波长反相高效液相色谱（RP-HPLC）法同时测定蓝芩口服液中栀子苷、绿原酸和黄芩苷含量的方法。方法：色谱柱Shimadzu C18（250 mm×4.6 mm,5 μm）,流动相乙腈（A）-0.3%磷酸水溶液（B）,梯度洗脱模式,栀子苷、绿原酸检测波长254 nm,黄芩苷检测波长280 nm,柱温30 ℃,进样量20 μL。结果：栀子苷、绿原酸和黄芩苷分别在1.05~209.20 μg/mL、0.50~99.20 μg/mL和0.52~103.00 μg/mL浓度范围内与峰面积线性关系良好,平均加样回收率分别为100.11%、99.93%和100.45%,RSD分别为1.84%、2.53%和1.30%。结论：该法简便、快速、灵敏,可用于蓝芩口服液中栀子苷、绿原酸和黄芩苷的含量测定。     

Nachweis einiger Heilmittel in der Kniegelenksynovialflüssigkeit

Zusammenfassung Mittels Gaschromatographie und Dünschichtchromatographie wiesen die Autoren 11 Substanzen nach, welche durch Injektion oder nach Verabreichung per os in die Kniegelenksynovialflüssigkeit eindrangen. In ihrer Aufstellung konnten sie eine direkte Beziehung zwischen Struktur sowie chemischphysikalischen Eigenschaften der Substanz und ihrer Fähigkeit, aus dem Blut in die Kniegelenksynovialflüssigkeit einzudringen, nicht nachweisen, außer der Tatsache, daß Substanzen mit starker Affinität zu Eiweißstoffen erst in höheren Dosen nachweisbar waren.     

Synthesis,Cytotoxicity and Antileishmanial Activity of Some N-(2-(indol-3-yl)ethyl)-7-chloroquinolin-4-amines

We report herein the condensation of 4,7-dichloroquinoline (1) with tryptamine (2) and D-tryptophan methyl ester (3) . Hydrolysis of the methyl ester adduct (5) yielded the free acid (6) . The compounds were evaluated in vitro for activity against four different species of Leishmania promastigote forms and for cytotoxic activity against Kb and Vero cells. Compound (5) showed good activity against the Leishmania species tested, while all three compounds displayed moderate activity in both Kb and Vero cells.     

Emerging drugs for epilepsy

Epilepsy affects ≤ 1% of the world's population. Antiepileptic drugs (AEDs) are the mainstay of treatment, although more than a third of patients are not rendered seizure free with existing medications. Uncontrolled epilepsy is associated with increased mortality and physical injuries, and a range of psychosocial morbidities, posing a substantial economic burden on individuals and society. Limitations of the present AEDs include suboptimal efficacy and their association with a host of adverse reactions. Continued efforts are being made in drug development to overcome these shortcomings employing a range of strategies, including modification of the structure of existing drugs, targeting novel molecular substrates and non-mechanism-based drug screening of compounds in traditional and newer animal models. This article reviews the need for new treatments and discusses some of the emerging compounds that have entered clinical development. The ultimate goal is to develop novel agents that can prevent the occurrence of seizures and the progression of epilepsy in at risk individuals.     

盐酸达泊西汀中甲磺酸甲酯、甲磺酸乙酯及甲磺酸异丙酯的顶空毛细管GC-ECD法测定

建立了衍生化顶空毛细管气相色谱-电子捕获检测器(ECD)法测定盐酸达泊西汀中的甲磺酸甲酯(MMS)、甲磺酸乙酯(EMS)和甲磺酸异丙酯(IMS).应用碘化钠衍生技术,使用PW-5毛细管柱,载气为氮气,ECD检测,程序升温.MMS、EMS和IMS分别在0.03～0.30、0.05～0.50和0.05～0.50 μg/ml浓度范围内线性关系良好,平均回收率分别为63.5％、100.3％和96.2％,最低检测限分别为0.30、0.50和0.50 ng/ml.     

Lung disease and PKCs

The lung offers a rich opportunity for development of therapeutic strategies focused on isozymes of protein kinase C (PKCs). PKCs are important in many cellular responses in the lung, and existing therapies for pulmonary disorders are inadequate. The lung poses unique challenges as it interfaces with air and blood, contains a pulmonary and systemic circulation, and consists of many cell types. Key structures are bronchial and pulmonary vessels, branching airways, and distal air sacs defined by alveolar walls containing capillaries and interstitial space. The cellular composition of each vessel, airway, and alveolar wall is heterogeneous. Injurious environmental stimuli signal through PKCs and cause a variety of disorders. Edema formation and pulmonary hypertension (PHTN) result from derangements in endothelial, smooth muscle (SM), and/or adventitial fibroblast cell phenotype. Asthma, chronic obstructive pulmonary disease (COPD), and lung cancer are characterized by distinctive pathological changes in airway epithelial, SM, and mucous-generating cells. Acute and chronic pneumonitis and fibrosis occur in the alveolar space and interstitium with type 2 pneumocytes and interstitial fibroblasts/myofibroblasts playing a prominent role. At each site, inflammatory, immune, and vascular progenitor cells contribute to the injury and repair process. Many strategies have been used to investigate PKCs in lung injury. Isolated organ preparations and whole animal studies are powerful approaches especially when genetically engineered mice are used. More analysis of PKC isozymes in normal and diseased human lung tissue and cells is needed to complement this work. Since opposing or counter-regulatory effects of selected PKCs in the same cell or tissue have been found, it may be desirable to target more than one PKC isozyme and potentially in different directions. Because multiple signaling pathways contribute to the key cellular responses important in lung biology, therapeutic strategies targeting PKCs may be more effective if combined with inhibitors of other pathways for additive or synergistic effect. Mechanisms that regulate PKC activity, including phosphorylation and interaction with isozyme-specific binding proteins, are also potential therapeutic targets. Key isotypes of PKC involved in lung pathophysiology are summarized and current and evolving therapeutic approaches to target them are identified.